Inhalation Home

The only technical publication devoted exclusively to readers involved in development
and production of orally inhaled and nasal delivered pharmaceuticals.

Slide background
Slide background
Slide background
Slide background


Discover the Capsugel® Dry Powder Inhalation Capsule Portfolio

Date: May 23, 2019

Time: 11:00 AM ET

Cost: FREE

Presented by:

Claire Tardy, Ph.D., Research and Development   Manager

Frederique Bordes-Picard, Manager, Business   Development for Innovative Products

Shiala George, Marketing Manager for the Americas,   Capsule Delivery Solutions

Moderated by: Lonza

Can’t attend?

If you register for a webinar but can’t attend the live event, an archived version will be accessible online for 30 days once it concludes. This allows you to view the entire webinar presentation and Q&A session at a time most convenient to your schedule.

Webinar Details: Dry powder inhalation is a major drug delivery technology for the treatment of respiratory diseases and, increasingly, for systemic drug delivery. Providing a uniform dose in a portable, easy-to-use system, capsule-based dry powder inhalers (DPIs) are a simple and cost-effective way to deliver medication by the pulmonary route.

Polymer science and engineering have opened a new era of functional development, which offers the potential for selecting the optimal capsule for different active pharmaceutical ingredients (APIs) and various inhalation devices. These capabilities also can be associated with a wider range of services.

Within the dry powder inhalation application fields, Lonza offers a portfolio of high-quality capsule solutions based on different polymers, tailored to enable consistent and optimal release performance. Building on a history of innovation in polymer science and capsule engineering, the Capsugel® brand, now part of Lonza, offers a suite of HPMC and alternate polymer capsules for the pharmaceutical world.